Consultation on proposed new risk management action for 2-butanone, oxime

Current status: Closed

Opened on July 15, 2022 and closed to new input on October 13, 2022.

A performance measurement evaluation of risk management actions currently in place for 2-butanone, oxime (also known as butanone oxime or methyl ethyl ketoxime) concluded that risks identified in the screening assessment are not effectively managed at this time. As such, the purpose of the consultation document is to consult interested stakeholders on proposed new risk management actions for 2-butanone, oxime in certain products available to consumers, particularly paints and coatings; stains and finishes; and adhesives and sealants.

Join in: how to participate

Please read the Consultation document on proposed new risk management action for 2-butanone, oxime, consider the key questions below, and send us your comments.

Send us an email
Send an email to chemicalsubstanceschimiques@hc-sc.gc.ca with your ideas or comments to make yourself heard.

Participate by mail
Send a letter with your ideas and input to the address in the contact information below.

Who is the focus of this consultation

We will engage with:

Key questions for discussion

Your ideas and inputs are sought around new risk management actions for 2-butanone, oxime (also known as butanone oxime or methyl ethyl ketoxime) in certain products available to consumers, particularly:

For these products the department is requesting information on:

The input gathered through this process will be used in the development of new risk management actions.

Related information

Contact us

Andrew Beck
Director, Risk Management Bureau
Health Canada
Mail stop PL 4905B
Ottawa, ON K1A 0K9
Email: chemicalsubstanceschimiques@hc-sc.gc.ca

Page details

Date modified: